Tuberculous and Non-Tuberculous Granulomatous Lymphadenitis in Patients Receiving Imatinib Mesylate (Glivec) for Metastatic Gastrointestinal Stromal Tumor

BACKGROUND: Imatinib mesylate (IM) is the standard treatment for BCR-ABL-positive chronic myelogenous leukemia (CML) and is the first-line adjuvant and palliative treatment for metastatic and inoperable gastrointestinal stromal tumor (GIST). IM is not known to be associated with an increased risk fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Agaimy, Abbas, Brueckl, Valeska, Schmidt, Daniela, Krieg, Stephanie, Ullrich, Evelyn, Meidenbauer, Norbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2013
Materias:
Published online: March, 2013
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618090/
https://www.ncbi.nlm.nih.gov/pubmed/23569448
http://dx.doi.org/10.1159/000348712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618090/
https://www.ncbi.nlm.nih.gov/pubmed/23569448
http://dx.doi.org/10.1159/000348712

Ejemplares similares